SG Urges Justices To Hear Hikma’s ‘Skinny Label’ Patent Case
By Editorial Team
The U.S. solicitor general has urged the U.S. Supreme Court to consider Hikma Pharmaceuticals Inc.’s appeal regarding a patent lawsuit involving its “skinny label” on a generic heart drug. The solicitor general expressed concerns that the decision to revive the patent suit could jeopardize the availability of lower-cost generics.
Hikma Pharmaceuticals Inc. has been embroiled in a legal battle over its generic heart drug, with a patent suit involving its “skinny label” at the center of the dispute. The U.S. solicitor general has intervened, urging the Supreme Court to take up the case and provide clarity on the issue.
The solicitor general’s intervention comes after a decision that revived the patent suit, raising concerns about the potential impact on the availability of affordable generic medications. The case has significant implications for the pharmaceutical industry and consumers who rely on generic drugs for cost-effective healthcare options.
The patent in question, numbered 9,700,537, pertains to a composition for preventing cardiovascular events in multiple-risk patients. Additionally, patent number 10,568,861 covers methods of reducing the risk of cardiovascular events in subjects at risk for cardiovascular disease.
Law firms Perkins Coie and Winston & Strawn are representing the parties involved in the case. Hikma Pharmaceuticals PLC is the company at the center of the dispute, with the Food and Drug Administration and the U.S. Supreme Court also playing key roles in the legal proceedings.
The outcome of this case could have far-reaching implications for the pharmaceutical industry, patent law, and the availability of affordable generic medications for consumers. The Supreme Court’s decision to hear the case will be closely watched by stakeholders across the healthcare and legal sectors.
